NMOSD

Recent MR analysis uncovers protein associations with neuromyelitis optica spectrum disorder, suggesting new treatment pathways and drug targets for improved management.

A review highlighted the role of serum neurofilament light chain as a potential biomarker in MOG antibody-associated disease, with findings pointing to associations with attack severity.

A recently published population-based study reported that patients with MS or NMOSD had a significantly higher risk of autoimmune rheumatic diseases than matched controls.

A 17-year-old with NMOSD and rituximab treatment developed PML after several relapses and secondary hypogammaglobulinemia, leading to his death 3 months after diagnosis.

Sumaira Ahmed, founder and executive director of The Sumaira Foundation, discussed how FDA-approved therapies transformed the NMOSD treatment landscape and highlighted ongoing challenges in patient care.

A global cohort study identified distinct clinical patterns and higher relapse rates in pediatric patients with MOGAD with non-P42 MOG antibody binding profiles.

Treatment strategies varied across cases, incorporating therapies like prednisolone, rituximab, and azathioprine, with overall positive outcomes and symptom improvement.

A post-hoc analysis of patients from the CHAMPION-NMOSD trial revealed that the majority received their initial meningococcal vaccination within 6-months of their last rituximab dose.

A recent study reported that the presence of oligoclonal bands in cerebrospinal fluid of patients with myelin oligodendrocyte glycoprotein antibody-associated disease may be associated with a higher risk of relapse.

A newly developed advanced fMRI-based classification model demonstrated efficacy in distinguishing multiple sclerosis from neuromyelitis optica spectrum disorder, potentially having the ability to improve diagnostic accuracy.

Cerebrospinal fluid lipid profiling revealed potential biomarkers for distinguishing NMOSD from MS and tracking disease activity, offering new insights into neuroinflammatory disease monitoring.

The assistant professor in the neurology department at the University of Utah in Salt Lake City provided a clinical overview of the new and old therapies for NMOSD, and how clinicians should go about choosing for their patients. [WATCH TIME: 6 minutes]

A recent study reported significantly elevated cerebrospinal fluid inflammatory markers in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease during acute phases.

A 5-year retrospective analysis offered insights into disease characteristics, treatment responses, and clinical outcomes of neuromyelitis optica spectrum disorder as well as myelin oligodendrocyte glycoprotein antibody-associated disease.

A significant number of pregnancies in NMOSD patients experienced relapses postpartum, with 50% of pregnancies showing complications for both mother and fetus.

A large registry-based study analyzed treatment patterns and attack risks in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

A unique case highlighted the complex interplay between NMOSD and other autoimmune diseases, demonstrating the challenges in diagnosing and managing the condition.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromyelitis optica spectrum disorder.

A 51-year-old patient with neuromyelitis optica spectrum disorder and hemorrhagic longitudinally extensive transverse myelitis presented a challenging case.

These findings underscore the potential of advanced imaging technologies to detect subtle gray matter differences, aiding in the accurate differentiation between MS and NMOSD.

A new study suggests particulate matter exposure exacerbated the severity of multiple sclerosis and neuromyelitis optica spectrum disorder, with significant clinical and radiological impacts.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune CNS condition with distinct subtypes—AQP4-IgG positive, MOGAD, and double-negative—each requiring tailored diagnostic and treatment approaches.

The associate professor of neurology at Harvard Medical School talked about reconsidering therapy switches for NMOSD, incorporating safety failures like recurrent infections, and prioritizing real-world studies to validate findings. [WATCH TIME: 5 minutes]

Patients who started therapy immediately after the initial attack had a relapse risk of just 11% at 2 years and 20% at 6 and 8 years, compared to much higher rates (41% at 2 years, 56% at 8 years) in those who delayed therapy until a second attack.

Ultimately, the biomarkers' temporal patterns may help differentiate attacks from remission, with sGFAP being particularly useful in distinguishing genuine attacks from pseudoattacks.

A recent multicenter study showed that dried blood spot testing for neuromyelitis optica spectrum disorder provided high accuracy and practicality in resource-limited settings.

A new study revealed stark racial and socioeconomic disparities in pediatric neuromyelitis optica spectrum disorder outcomes, underscoring the need for targeted interventions.

In a longitudinal study lasting 2 years, impaired test performance in semantic fluency and congruent speed were observed in patients with MOGAD relative to healthy controls.

The phase 1 study, which is currently recruiting, includes a 4-week screening period, a 52-week treatment period, and a 4-year long-term extension to continue to test the effects of HG202.

HNSA-5487 exhibited lower pre-treatment anti-drug antibody levels and reduced ADA responses compared to imlifidase, indicating a favorable immunogenicity profile and strong potential for redosing, with no serious adverse events observed.